Share Twitter LinkedIn Facebook Email Dr. Lowell Hart, MD, Director of Research, Florida Cancer Specialists and Research Institute shares the mechanism of action for trilacicnib and the importance of protecting the bone marrow.
VIDEO: FDA Approves Atezolizumab / Tecentriq Hybreza For Subcutaneous PD-(L)1 Cancer Immunotherapy in NSCLC Kidney 4 Mins Read
Lurbinectedin: Enhancing Immunotherapy Efficacy in Small Cell Lung Cancer Small Cell Lung Cancer 3 Mins Read
